AstraZeneca’s chief executive David Brennan has maintained he will be staying in the top role despite speculation surrounding the company’s future. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/azs_ceo_says_he_is_staying_977491Bristol-Myers Squibb has submitted new drug applications with US regulators for hepatitis C drugs daclatasvir and asunaprevir. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/bms_submits_hep_c_drugs_in_the_usa_1001787Analysts are predicting UK pharma giant GlaxoSmithKline will be hitting a £3 billion jackpot by the end of the year following demand for its swine flu vaccine Pandemrix. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/3bn_windfall_predicted_for_gsk_984494Pharmaceutical company Biovitrum has taken on three of Amgen’s biologics products in a deal worth more than $130 million. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/biovitrum_takes_on_amgen_products_987853The US Food and Drug Administration has given the green light to AstraZeneca’s bipolar extended release treatment Seroquel XR (quetiapine fumarate). - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/seroquel_xr_gets_approved_in_the_usa_986614Abbott has announced it will repurchase $5 billion worth of the company’s shares in a bid to strengthen its stock, which has seen a 12% drop this year. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/abbott_buys_back_$5_billion_worth_of_stock_986602US regulators have seized 11 lots of contaminated blood-thinner heparin from Celsus Laboratories in Cincinnati, Ohio. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/us_seizes_contaminated_blood-thinner_986426MannKind Corporation is to cut 41% of its workforce as it struggles to get its foot in the approval door at the US Food and Drug Administration. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/mann_unkind_to_mannkind_workforce_979611The pressure of Eli Lilly’s looming patent cliff has beenreduced after a US Committee has recommended expanding the pain indication forits top selling drug Cymbalta (duloxetine HCL). - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/cymbalta_gets_support_for_broader_use_982566Pfizer’s HIV drug Selzentry (maraviroc) has been backed by a US Food and Drug Administration panel recommending broader use of the currently limited access drug. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/pfizers_hiv_drug_gets_a_positive_boost_984483
